Medtronic is a global leader in medical technology, focused on developing and providing innovative therapeutic solutions to improve the lives of patients. The company specializes in a wide range of medical devices and therapies, addressing conditions in areas such as diabetes care, cardiovascular health, surgical innovations, and neurological disorders. Medtronic is committed to advancing healthcare through cutting-edge research, collaboration with healthcare providers, and a strong emphasis on patient-centered care, aiming to enhance the quality of life for millions around the world. Read More
United States - 29th May, 2025 - As hernia mesh lawsuits continue to progress against major medical device manufacturers, Mayfair Legal Funding is stepping forward with financial solutions to support plaintiffs awaiting settlements. As a trusted provider of pre-settlement funding, Mayfair is committed to helping victims of defective hernia mesh implants manage their financial needs while pursuing justice.
The company said in a regulatory filing that the decision was made in light of increased clinical and regulatory requirements to maintain regulatory approvals in global markets and to obtain approvals in new regions.
Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Thursday as we examine the latest happenings in today's session.
U.S. equities trading was mixed on Wednesday, with major indices showing limited movement by midday as investors remained cautious amid renewed concerns over fiscal policy, which pressured Treasury bonds and the dollar.
Ireland has emerged as the undisputed champion in attracting U.S. foreign direct investment, hosting an extraordinary €897 billion (over $1 trillion) in American capital. This massive investment flow has transformed the small island nation into America's premier European platform, with U.S. affiliate assets reaching approximately $2 trillion in 2021.
NEW HOPE, Pa., May 12, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced financial results for the first quarter ended March 31, 2025, and provided a business update highlighting continued regulatory momentum, disciplined operational execution, and a strengthening clinical development pipeline.
